A Pilot Study of Low Dose ARA-C, Interferon-Alpha and Cis-Retinoic Acid (AIR) Combination Therapy for Poor Risk Patients with Acute Myeloid Leukaemia.
20 adult patients with acute myeloid leukaemia who were considered not suitable for or resistant to conventional chemotherapy were entered into a pilot study of low dose ARA-C, Interferon-alpha and cis-retinoic acid (AIR) combination therapy. The overall response rate was 35%, with 4/20 patients achieving complete remission and 3/20 partial remission. There was also favourable duration of survival among the responders. AIR therapy was well tolerated and was given on an out-patient basis. Hospital admission was minimum during the period of treatment. Most patients however required out-patient support of blood and platelet transfusion. These results indicate that AIR therapy may be beneficial in a selected group of poor risk patients with AML. Further evaluation is needed to identify parameters predictive of response.